Danaher Corporation (DHR) is listed on NYSE in the Healthcare sector Β· Diagnostics & Research industry. The current price is 208.69, down -0.58% from the previous close. Market cap is approximately $146.7B.
The commentary below is auto-generated by comparing market data (P/E, ROE, D/E, etc.) against predefined thresholds. No LLM is used. This is not a buy/sell recommendation from us or any analyst. For reference only.
A P/E of 37.27x reflects strong expectations for future earnings growth. Multiple compression often starts the first quarter growth decelerates.
A low ROE of 7.61% is common in capital-heavy sectors (utilities, heavy industry, infrastructure) or after large equity raises.
Danaher Corporation's elevated D/E of 52.97 either reflects an aggressive growth-via-debt strategy or balance sheet stress. Operating cash flow trend is the cleanest tell.
DHR's 5.50% revenue growth is modest. In this band, buybacks and dividends often drive most of the EPS and total return.
Dividend yield of 0.76% is on the low side. Capital is more likely going to reinvestment and buybacks than payouts.
Pharma and biotech are typically valued through risk-adjusted NPV/DCF on the pipeline.
Danaher Corporation trades near the midpoint (42%) of its 52-week range (160.93β242.80). With the price anchored to neither extreme, valuation and earnings tend to be more informative than price direction here.
Your watchlist and portfolio, one tap from your home screen β the Margin Call app
The day's high-to-low spread reached 3.44%, with a -0.58% move. Wide sessions frequently follow earnings, filings, or sector news, so identifying the catalyst matters.
Danaher Corporation (DHR) is listed on NYSE, with recent volume of 1,098,663 shares. Volume is a supporting gauge of how much conviction sits behind a price move β the same gain reads differently on heavy versus light turnover.